证券代码：002900 证券简称：哈三联 公告编号：2026-001 会议审议并通过以下议案： 哈尔滨三联药业股份有限公司 第五届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下或简称"公司"）第五届董事会第 二次会议于 2026 年 1 月 28 日以微信、电子邮件形式向全体董事发出通知。 2、本次会议于 2026 年 1 月 28 日以通讯表决的方式召开。 3、本次会议应出席董事 9 人，实际出席会议的董事 9 人。 4、会议由董事长秦剑飞先生主持。 5、本次会议的通知、召集和召开符合《中华人民共和国公司法》（以下简 称"《公司法》"）等法律、行政法规、部门规章、规范性文件及《哈尔滨三联 药业股份有限公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过《关于豁免第五届董事会第二次会议提前通知的议案》 全体董事一致同意豁免本次会议提前 2 日通知的时限要求，同意于 2026 年 1 月 28 日召开第五届董事会第二次会议。 表决情况：有效表决 9 票，同意 9 票， ...

Group 1 - The company, Ha Sanlian (002900), reported that as of January 9, 2026, the number of shareholders is 36,960 [2]

Group 1 - The core point of the article is that as of January 9, 2026, the number of shareholders for the company is reported to be 36,960 [2]

Group 1 - The report highlights that the Heilongjiang Airport Group achieved record transportation volumes in 2025, with 205,000 flight takeoffs and landings, 29.064 million passengers, and 154,000 tons of cargo, representing year-on-year growth of 1%, 1.2%, and 4.8% respectively [3][9] - The group has expanded its domestic and international routes to 363, connecting 112 cities, and is promoting the integration of "aviation + tourism" to enhance local economic development [3][9] - The report notes the launch of a new consumption upgrade policy in Heilongjiang, providing subsidies for replacing old vehicles and purchasing energy-efficient appliances, aimed at stimulating consumer spending [5][10] Group 2 - The report indicates that the Heilongjiang sector index rose by 4.82% in December 2025, outperforming the Shanghai and Shenzhen indices, with a notable divergence in the performance of listed companies [19][25] - Five companies in the province saw significant gains, with Guanglian Aviation leading at 112.11%, followed by Aerospace Science and Technology (+51.11%) and New Light Optoelectronics (+41.21%) [25][26] - Conversely, 24 companies reported negative returns, with four companies experiencing declines exceeding 10%, including Renmin Tongtai (-14.68%) and Fuerjia (-14.51%) [25][26] Group 3 - The report emphasizes the integration of industry and technology, citing the launch of the Huagong Technology Intelligent Manufacturing Northern Headquarters in Harbin, which focuses on the development of intelligent laser weeding robots [12][13] - The project, with an investment of 100 million yuan and an annual production capacity of 200 units, aligns with the "storing grain in the ground and technology" strategy, showcasing the region's commitment to technological advancement [12][13] - The report also mentions the CE certification obtained by the Kando robot from Harbin, which signifies its readiness for the European market, reflecting the growing recognition of Chinese manufacturing in the global arena [11]

Group 1 - The company, Harbin Three Links (002900.SZ), currently has no collaboration with Alibaba Health [1]

Group 1 - The core point of the article is that the company, 哈三联 (002900.SZ), has stated there is currently no collaboration with 阿里健康 [1] Group 2 - The company has communicated this information through an interactive platform [1]

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. has shown a mixed performance in stock price and financial results, with a notable increase in stock price year-to-date but significant declines in revenue and net profit for the recent period [1][2]. Group 1: Stock Performance - As of December 18, Harbin Sanlian's stock price increased by 2.10% to 13.15 CNY per share, with a trading volume of 41.03 million CNY and a turnover rate of 1.81%, resulting in a total market capitalization of 4.16 billion CNY [1]. - Year-to-date, the stock price has risen by 36.27%, but it has experienced a decline of 1.79% over the last five trading days, 4.29% over the last 20 days, and 4.15% over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a stock market leaderboard) nine times this year, with the most recent appearance on June 3 [1]. Group 2: Financial Performance - For the period from January to September 2025, Harbin Sanlian reported a revenue of 581 million CNY, representing a year-on-year decrease of 30.75%, and a net profit attributable to shareholders of -209 million CNY, a significant decline of 614.61% [2]. - The number of shareholders as of December 10 is 38,100, which is a decrease of 4.00% from the previous period, while the average number of circulating shares per person increased by 4.16% to 4,594 shares [2]. Group 3: Business Overview - Harbin Sanlian, established on June 21, 1996, and listed on September 22, 2017, is primarily engaged in the research, production, and sales of chemical drug formulations [1]. - The revenue composition of the company includes: large-volume injections (32.00%), lyophilized powder injections (18.39%), solid preparations (17.39%), small-volume injections (14.34%), and other segments [1]. - The company operates within the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors such as hypertension treatment, anti-influenza, hepatitis treatment, innovative drugs, and pet economy [1]. Group 4: Dividend Information - Since its A-share listing, Harbin Sanlian has distributed a total of 677 million CNY in dividends, with 158 million CNY distributed over the past three years [3].

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Harbin Longjiang Animal Health Biotechnology Co., Ltd., has changed its business scope and completed the registration with the industrial and commercial authorities, obtaining a new business license [1]. Group 1: Business Scope Change - The business scope of Harbin Longjiang Animal Health Biotechnology Co., Ltd. has been updated to include "Internet sales (excluding goods that require permits)" and "food internet sales (only for pre-packaged food)" [1]. - The previous business scope included various activities such as veterinary drug production, veterinary drug operation, and feed additive production, which remain unchanged in the new scope [1]. Group 2: Regulatory Compliance - The company confirmed that all other registration details in the business license remain unchanged, ensuring compliance with relevant regulatory requirements [1].

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Harbin Longjiang Animal Health Biotechnology Co., Ltd., has changed its business scope and completed the registration procedures, obtaining a new business license from the Harbin New Area Management Committee [1]. Group 1: Business Scope Change - The business scope before the change included veterinary drug production, veterinary drug operation, and feed additive production, along with various technical services and sales [1]. - The new business scope retains the previous items and adds internet sales (excluding goods requiring permits) and food internet sales (only for pre-packaged food) [1]. - Other registration items in the business license of Harbin Longjiang Animal Health Biotechnology Co., Ltd. remain unchanged [1].

Group 1 - The core point of the article is that the company, 哈三联 (002900), has reported that as of December 10, 2025, the number of its shareholders will be 38,083 households [1]